Anil Shankar is a partner and health care lawyer with Foley & Lardner LLP, and a member of the firm’s Health Care Practice. He provides strategic counsel to health care providers as they navigate complex regulatory and reimbursement matters, with a particular focus on the Medicaid program and issues affecting safety net providers.
Anil has been recognized by Chambers USA: America’s Leading Business Lawyers:
““He’s smart, patient and always comes up with creative solutions to complicated problems.”
“We often ask Anil to work on thorny issues that he parses with sophistication and nuance that is essential to solving problems.”
Anil is a lecturer at the UCLA School of Law, where he teaches Health Care Compliance.
Medicaid Experience
Anil advises hospitals, clinics, health systems, other providers, managed care plans, and governmental entities on their participation in Medicaid programs. He has helped develop innovative new programs, including Medicaid supplemental payments, quality networks, state and local provider taxes or assessments, and public-private partnerships. He has extensive experience in the use of health care funding to address the social determinants of health and helped to design and implement California’s Whole Person Care pilots, which operate innovative programs for individuals experiencing homelessness, individuals leaving incarceration, individuals with significant mental health disorders, and other vulnerable populations.
He advises clients on a numerous Medicaid reimbursement and compliance issues, including overpayment investigations and analyses. He has also assisted numerous companies seeking to enter into the Medicaid program. Anil also has deep knowledge of Medicaid managed care and has helped plans and providers evaluate regulatory changes and structure alternative payment methodologies to meet their goals.
340B Drug Pricing Program
Anil heads the firm’s robust 340B Drug Pricing Program practice, which counsels hospital systems, federally qualified health centers, and federal grantees with regard to their obligations and opportunities under the program. He advises clients on compliance and overpayment issues, self-disclosures, internal and governmental audits, 340B contracting, and has helped to restructure entities to maximize 340B Program savings.
Verhaltensbiologische Gesundheit
Anil has extensive experience advising clients on behavioral health reimbursement, operational, and compliance issues. He has counseled hospitals on health systems seeking to expand their behavioral health offerings, including strategic counseling to avoid licensing, regulatory, and reimbursement pitfalls. In addition, Anil has helped design systems to protect and share confidential patient information, including behavioral health information. He works with local behavioral health directors, providers, and managed delivery systems on issues related to funding, reimbursement, program development, and strategic implementation.
Auditing and Compliance
Anil advises health care providers and companies to track and oversee federal grants and reimbursement, including hemophilia treatment center funds, Ryan White funds, 340B funds, FQHCs, and has advised them during related audits. During the coronavirus pandemic, Anil advised hospitals, health systems, governmental entities, nursing facilities and other health care providers and companies with regard to their application, receipt and use of federal relief funds, including the Provider Relief Fund and Coronavirus Relief Fund. He has recovered millions of dollars by successfully challenging Medicaid reimbursement audit findings.
Auszeichnungen und Anerkennungen
- Chambers USA, Health Care Law (2022 and 2024)
Zugehörigkeiten
- Faculty lecturer at the UCLA School of Law
- Mitglied der American Health Lawyer’s Association (Amerikanische Vereinigung der Gesundheitsrechtsanwälte)
- Mitglied der Anwaltskammer des Bezirks Los Angeles (Sektion Gesundheitsrecht)
- Member, American Bar Association (Health Law Section)
Veröffentlichungen und Präsentationen
- Mitautor, „Behörde in Kalifornien geht gegen hochpreisige Krankenhäuser vor“, Health Care Law Today (6. Mai 2025)
- Co-author, “The 340B Drug Pricing Program: Top Five Things to Know,” Health Care Law Today (September 17, 2024)
- Co-speaker, “Strategies for Working with and Discharging Homeless Populations,” Hospital Association of Southern California’s 2024 Annual Meeting (May 21, 2024)
- Author, “Medicaid: CMS Final Rules Aim to Expand Access, Provide Parity with Commercial Markets,” Health Care Law Today (May 13, 2024)
- Co-author, “Health-Related Social Needs: Three Trends in Leveraging Community Partnerships,” Health Care Law Today (March 27, 2024)
- Co-author, “CMS Proposes Remedy for 340B-Acquired Drug Payment Policy for CY 2018-2022,” Health Care Law Today (July 26, 2023)
- Co-author, “The Future of the 340B Program: 2023 Key Decisions,” Health Care Law Today (March 30, 2023)
- Co-speaker, “Social Determinants of Health,” What You Need to Know About Payor/Provider Convergence (Jan 26, 2023)
- Moderator, “The Urgency of Behavioral Health Integration and Whole Person Care,” Moss Adams Conference (Nov. 3, 2022)
- Author, “California Moves to Transform the Behavioral Health Delivery System – Are Payers and Providers Ready?,” Health Care Law Today (Oct. 31, 2022)
- Co-author, “340B Hospitals Win in Medicare OPPS Supreme Court Decision,” Health Care Law Today (June 21, 2022)
- Co-speaker, “Strategies for Difficulty to Discharge Patients,” California Association of Public Hospitals member meeting (December 8, 2021)
- Presenter, “PRF Reporting,” California Association of Public Hospitals and Health Systems member meeting (September 16, 2021)
- Co-author, “Payment Dispute with a Medicaid Health Plan? State Not Obligated to Help, According to Federal Court,” Health Care Law Today (July 14, 2021)
- Co-author, “Court Sides with Drug Manufacturers in Ongoing 340B Litigation,” Health Care Law Today (June 22, 2021)
- Co-author, “HHS Extends Timeline for Spending Provider Relief Fund,” Health Care Law Today (June 14, 2021)
- Co-author, “Congress Requires New Medicaid Payment Reporting,” Health Care Law Today (February 23, 2021)
- Co-author, “Congress Overrides HHS Guidance on Use of Provider Relief Funds,” Health Care Law Today (January 11, 2021)
- Co-author, “New HHS Board will Hear 340B Drug Pricing Disputes,” Health Care Law Today (December 15, 2020)
- Co-author, “COVID-19: Provider Relief Fund General Distribution – Phase 3,” Health Care Law Today (October 5, 2020)
- Co-author, “COVID-19: HHS Publishes Long-awaited Reporting Requirements for Provider Relief Fund Recipients,” Health Care Law Today (September 23, 2020)
- Co-author, “COVID-19: Take Two (for some) on Additional DHHS Provider Relief Funding,” Health Care Law Today (August 12, 2020)
- Co-presenter, “COVID-19 Provider Relief Funds – Use of Funds, Attestations, and Risk Analysis,” Foley & Lardner LLP Web Conference (April 28, 2020)
- Co-author, “COVID-19: Understanding HHS’s Plans to Disperse Provider Relief Funds Authorized By The CARES Act,” Health Care Law Today (April 27, 2020)
- Co-author, “COVID-19: Federal Agencies Prepare to Distribute Unprecedented Federal Financial Relief for the Health Care Industry,” Health Care Law Today (March 30, 2020)
- Co-author, “CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments,” Health Care Law Today (November 20, 2019)
- Co-author, “Voluntary Behavioral Health Integration in Medi-Cal: What Can be Achieved under Current Law,” California Health Care Foundation (October 21, 2019)
- Co-author, “Off-Campus Hospital Outpatient Departments Take Another Hit in CMS Final Rule,” Health Care Law Today (November 14, 2018)
- Co-author, “A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries,” Annals of Internal Medicine (July 17, 2018)
- Co-author, “Policy Brief: A novel strategy for increasing access to Hep C treatment for Medicaid beneficiaries,” USC-Brookings Schaeffer Initiative for Health Policy (May 2018)
- Co-author, “California: Proposed Legislation Regulating Health Care Rates for Payors and Providers,” Health Care Law Today (April 19, 2018)
- Co-author, “California Medicaid Agency Proposes Significant Restrictions on FQHC and RHC Reimbursement,” Health Care Law Today (March 13, 2018)
- Co-author, “SAMHSA Finalizes Second Round of Changes to Federal Substance Use Disorder Privacy Rule,” Health Care Law Today (January 11, 2018)
- Co-author, “Ninth Circuit Victory Opens Door to Medicaid Reimbursement Challenges Based on Equal Access Requirement,” AHLA Bulletin (August 2017)
Foley-Anwälte skizzieren die weitreichenden Änderungen von H.R. 1 an Medicaid
Wie H.R.1 die Medicaid-Budgets gekürzt hat: Was das für Sie bedeutet
/Passle/67196104ea6deed3d1072b7a/MediaLibrary/Images/2025-05-20-14-23-19-395-682c9057975255c097204ded.jpg)
Die HHS-Richtlinie zum Ausschluss nicht berechtigter Ausländer aus weiteren Bundesprogrammen wirft Fragen für Anbieter und Zuschussempfänger auf.
/Passle/67196104ea6deed3d1072b7a/SearchServiceImages/2025-07-17-13-45-04-950-6878fe602d1780b8749bc5f7.jpg)
Eine große schöne Rechnung: Gekürzte Budgets werden das Medicaid-Programm stören
/Passle/67196104ea6deed3d1072b7a/SearchServiceImages/2025-07-01-16-02-56-845-686406b0314be9321cfc86cb.jpg)